Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

Lily M. Du, Paquita Nurden, Alan T. Nurden, Timothy C. Nichols, Dwight A. Bellinger, Eric S. Jensen, Sandra L. Haberichter, Elizabeth Merricks, Robin A. Raymer, Juan Fang, Sevasti B. Koukouritaki, Paula M. Jacobi, Troy B. Hawkins, Kenneth Cornetta, Qizhen Shi, David A. Wilcox

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into a-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.

Original languageEnglish
Article number2773
JournalNature Communications
Volume4
DOIs
StatePublished - 2013

Fingerprint

hemostatics
gene therapy
Gene therapy
dogs
Hemophilia A
Platelets
platelets
Hemostasis
Genetic Therapy
Blood Platelets
Dogs
bleeding
Hemorrhage
therapy
Hemorrhagic Disorders
transplantation
stem cells
Vascular System Injuries
Factor VIII
von Willebrand Factor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Du, L. M., Nurden, P., Nurden, A. T., Nichols, T. C., Bellinger, D. A., Jensen, E. S., ... Wilcox, D. A. (2013). Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nature Communications, 4, [2773]. https://doi.org/10.1038/ncomms3773

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. / Du, Lily M.; Nurden, Paquita; Nurden, Alan T.; Nichols, Timothy C.; Bellinger, Dwight A.; Jensen, Eric S.; Haberichter, Sandra L.; Merricks, Elizabeth; Raymer, Robin A.; Fang, Juan; Koukouritaki, Sevasti B.; Jacobi, Paula M.; Hawkins, Troy B.; Cornetta, Kenneth; Shi, Qizhen; Wilcox, David A.

In: Nature Communications, Vol. 4, 2773, 2013.

Research output: Contribution to journalArticle

Du, LM, Nurden, P, Nurden, AT, Nichols, TC, Bellinger, DA, Jensen, ES, Haberichter, SL, Merricks, E, Raymer, RA, Fang, J, Koukouritaki, SB, Jacobi, PM, Hawkins, TB, Cornetta, K, Shi, Q & Wilcox, DA 2013, 'Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A', Nature Communications, vol. 4, 2773. https://doi.org/10.1038/ncomms3773
Du, Lily M. ; Nurden, Paquita ; Nurden, Alan T. ; Nichols, Timothy C. ; Bellinger, Dwight A. ; Jensen, Eric S. ; Haberichter, Sandra L. ; Merricks, Elizabeth ; Raymer, Robin A. ; Fang, Juan ; Koukouritaki, Sevasti B. ; Jacobi, Paula M. ; Hawkins, Troy B. ; Cornetta, Kenneth ; Shi, Qizhen ; Wilcox, David A. / Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. In: Nature Communications. 2013 ; Vol. 4.
@article{b0eb10870c8c48caaa28522b14536aac,
title = "Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A",
abstract = "It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into a-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.",
author = "Du, {Lily M.} and Paquita Nurden and Nurden, {Alan T.} and Nichols, {Timothy C.} and Bellinger, {Dwight A.} and Jensen, {Eric S.} and Haberichter, {Sandra L.} and Elizabeth Merricks and Raymer, {Robin A.} and Juan Fang and Koukouritaki, {Sevasti B.} and Jacobi, {Paula M.} and Hawkins, {Troy B.} and Kenneth Cornetta and Qizhen Shi and Wilcox, {David A.}",
year = "2013",
doi = "10.1038/ncomms3773",
language = "English",
volume = "4",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

AU - Du, Lily M.

AU - Nurden, Paquita

AU - Nurden, Alan T.

AU - Nichols, Timothy C.

AU - Bellinger, Dwight A.

AU - Jensen, Eric S.

AU - Haberichter, Sandra L.

AU - Merricks, Elizabeth

AU - Raymer, Robin A.

AU - Fang, Juan

AU - Koukouritaki, Sevasti B.

AU - Jacobi, Paula M.

AU - Hawkins, Troy B.

AU - Cornetta, Kenneth

AU - Shi, Qizhen

AU - Wilcox, David A.

PY - 2013

Y1 - 2013

N2 - It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into a-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.

AB - It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into a-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.

UR - http://www.scopus.com/inward/record.url?scp=84893419411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893419411&partnerID=8YFLogxK

U2 - 10.1038/ncomms3773

DO - 10.1038/ncomms3773

M3 - Article

C2 - 24253479

AN - SCOPUS:84893419411

VL - 4

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 2773

ER -